{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T07:53:30Z","timestamp":1775894010647,"version":"3.50.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Intermediate-risk prostate cancer (PCa) is usually treated by a combination of external beam radiation therapy (EBRT) and a short course of androgen deprivation therapy (ADT). ADT is associated with multiple side effects, including weight gain, loss of libido, and hot flashes. In contrast, anti-androgen monotherapy is generally better tolerated in spite of higher rates of gynecomastia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This study assessed the effectiveness of enzalutamide monotherapy combined with hypofractionated EBRT (Hypo-EBRT) for treating intermediate risk prostate cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>This trial was a multicenter, open-label phase II study of 6 months of enzalutamide monotherapy combined with Hypo-EBRT for intermediate-risk prostate cancer. Hypo-EBRT was initiated 8\u201312 weeks after initiating enzalutamide. The primary endpoint was PSA decline &amp;gt;80% measured at the 25th week of enzalutamide administration. Secondary end-points included assessment of toxicity, changes in anthropomorphic body measurements, sexual hormones, and metabolic changes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixty-two patients were included in the study from January 2018 to February 2020.\u00a0A PSA decline of &amp;gt;80% was observed in all evaluable patients at the end of enzalutamide treatment and 92% achieved PSA values under 0.1 ngr\/ml. All patients remain in PSA response (&amp;lt;80% reduction of the initial values) 6 months after the end of enzalutamide treatment. The most frequent adverse events were hypertension, asthenia, and gynecomastia. There were no significant changes in bone density, body mass index (BMI), or patient-reported outcomes (PROs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Enzalutamide monotherapy is very effective along with hEBRT in reducing PSA levels for patients with intermediate-risk prostate cancer. Longer follow-up is needed to confirm the potential use of this combination in future randomized trials.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.891886","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T04:32:30Z","timestamp":1657773150000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer"],"prefix":"10.3389","volume":"12","author":[{"given":"Pedro C.","family":"Lara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan I.","family":"Rodr\u00edguez-Melc\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"Palacios-Eito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asunci\u00f3n","family":"Herv\u00e1s-Mor\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Villafranca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"G\u00f3mez-Iturriaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"B1","unstructured":"NCCN Guidelines Version 32016"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2419","article-title":"Dose-Escalated Radiotherapy for Prostate Cancer: Is the Sky the Limit","volume":"1","author":"Gray","year":"2015","journal-title":"JAMA Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.4942","article-title":"Prostate Cancer and the Hypofractionation Hypothesis","volume":"31","author":"Lee","year":"2013","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3764","article-title":"Making Radiation Therapy for Prostate Cancer More Economical and More Convenient","volume":"34","author":"Zietman","year":"2016","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional Versus Hypofractionated High- Dose Intensity-Modulated Radiotherapy for Prostate Cancer: 5-Year Outcomes of the Randomised, non-Inferiority, Phase 3 CHHiP Trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03217","article-title":"Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials","volume":"38","author":"Jackson","year":"2020","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen Deprivation Therapy: Progress in Understanding Mechanisms of Resistance and Optimizing Androgen Depletion","volume":"6","author":"Harris","year":"2009","journal-title":"Nat Clin Pract Urol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eururo.2008.10.008","article-title":"Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks","volume":"55","author":"Isbarn","year":"2009","journal-title":"Eur Urol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0183","article-title":"Bone Loss After Initiation of Androgen Deprivation Therapy in Patients With Prostate Cancer","volume":"90","author":"Greenspan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09319.x","article-title":"Antiandrogen Monotherapy in Patients With Localized or Locally Advanced Prostate Cancer: Final Results From the Bicalutamide Early Prostate Cancer Programme at a Median Follow-Up of 9","volume":"105","author":"Iversen","year":"2010","journal-title":"7 Years BJU Int"},{"key":"B14","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30097-9","article-title":"Bicalutamide With Radiotherapy for Prostate Cancer","volume":"18","author":"Brower","year":"2017","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1126\/science.1168175","article-title":"Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.mce.2012.10.002","article-title":"FoxA1 Corrupts the Antiandrogenic Effect of Bicalutamide But Only Weakly Attenuates the Effect of MDV3100 (Enzalutamide\u2122)","volume":"365","author":"Belikov","year":"2013","journal-title":"Mol Cell Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S45703","article-title":"Enzalutamide as a Second Generation Antiandrogen for Treatment of Advanced Prostate Cancer","volume":"7","author":"Semenas","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.9285","article-title":"Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial","volume":"34","author":"Penson","year":"2016","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1410239","article-title":"Enzalutamide in Metastatic Prostate Cancer Before Chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"New Eng J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in Men With Nonmetastatic , Castration-Resistant Prostate Cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"New Eng J Med"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide With Standard First-Line Therapy in Metastatic Prostate Cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S1470-2045(14)70129-9","article-title":"Enzalutamide Monotherapy in Hormone-Naive Prostate Cancer: Primary Analysis of an Open-Label, Single-Arm, Phase 2 Study","volume":"15","author":"Tombal","year":"2014","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.01.027","article-title":"Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Hormone Na\u00efve Prostate Cancer: 1 and 2 Year Open-Label Follow Up Results","volume":"68","author":"Tombal","year":"2015","journal-title":"Eur Urol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.08.103","article-title":"Long-Term Activity and Safety of Enzalutamide Monotherapy in Hormone Na\u00efve Prostate Cancer: 3 Year Open Label Follow Up Results","volume":"199","author":"Tombal","year":"2018","journal-title":"J Urol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The Efficacy and Safety of Degarelix: A 12- Month, Comparative, Randomized, Open-Label, Parallel-Group Phase III Study in Patients With Prostate Cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00855","article-title":"Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease","volume":"39","author":"Bolla","year":"2021","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpor.2019.02.002","article-title":"Radiopotentiation of Enzalutamide Over Human Prostate Cancer Cells as Assessed by Real-Time Cell Monitoring","volume":"24","author":"Barrado","year":"2019","journal-title":"Rep Pract Oncol Radiother"},{"key":"B30","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1200\/JCO.2017.35.6_suppl.208","article-title":"Effect of Enzalutamide on Sensitivity in Prostate Cancer Cells to Radiation by Inhibition of DNA Double Strand Break Repair","volume":"35","author":"Ghashghaei","year":"2017","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214670","article-title":"Radiosensitization by Enzalutamide for Human Prostate Cancer is Mediated Through the DNA Damage Repair Pathway","volume":"14","author":"Sekhar","year":"2019","journal-title":"PLoS One"},{"key":"B32","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/pros.23445","article-title":"Enhanced Radiosensitization of Enzalutamide via Schedule Dependent Administration to Androgen-Sensitive Prostate Cancer Cells","volume":"78","author":"Ghashghaei","year":"2018","journal-title":"Prostate"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02438","article-title":"Roy S Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared toNeoadjuvant ADT: An Individual Patient Meta-Analysis","volume":"39","author":"Spratt","year":"2021","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.01.067","article-title":"Hypofractionated Intensity-Modulated Radiotherapy (70 Gy at 2.5 Gy Per Fraction) for Localized Prostate Cancer: Cleveland Clinic Experience","volume":"68","author":"Kupelian","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4321\/S0004-06142008000800017","article-title":"The Eortc Quality of Life Questionnaire QLQ-C30 (Version 3.0). Validation Study for Spanish Prostate Cancer Patients","volume":"61","author":"Arraras Urdaniz","year":"2008","journal-title":"Arch Esp Urol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/S12094-009-0332-z","article-title":"The EORTC Quality of Life Questionnaire for Patients With Prostate Cancer: EORTC QLQ-PR25. Validation Study for Spanish Patients","volume":"11","author":"Arraras","year":"2009","journal-title":"Clin Transl Oncol"},{"key":"B37","volume-title":"A: A Language and Environment for Statistical Computing","year":"2021"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.02.027","article-title":"Enzalutamide With Radiation Therapy for Intermediate-Risk Prostate Cancer: A Phase 2 Study","volume":"110","author":"Kaplan","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.4189","article-title":"Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial","volume":"35","author":"Arcangeli","year":"2017","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.12.160","article-title":"Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial","volume":"113","author":"Tree","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.11.033","article-title":"Estimation of a Self-Consistent Set of Radiobiological Parameters From Hypofractionated Versus Standard Radiation Therapy of Prostate Cancer","volume":"85","author":"Pedicini","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.891886\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T04:32:42Z","timestamp":1657773162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.891886\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":41,"alternative-id":["10.3389\/fonc.2022.891886"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.891886","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]},"article-number":"891886"}}